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Available online 10 May 2016Aims: Bile acids (BAs) are important gut signaling hormones, inﬂuencing lipid, glucose, and energy homeostasis.
The exact mechanisms behind these effects are not yet fully understood. Lately, they have come to the fore as
putative therapeutics in metabolic diseases, such as e.g. nonalcoholic fatty liver disease (NAFLD). We elucidate
to what extent BAs impacts on the mRNAome and microRNAome in hepatocytes to gather novel insights into
the mechanisms behind metabolic and toxicologic effects of bile acids.
Main methods: Five batches of primary human hepatocytes were treated with 50 μmol/l chenodeoxycholic acid
(CDCA) for 24 or 48 h. Total RNA was extracted, size fractionated and subjected to Next Generation Sequencing
to generate mRNA and miRNA proﬁles.
Key ﬁndings: Expression of 738 genes and 52 miRNAs were CDCA dependently decreased, whereas 1566 genes
and 29 miRNAs were signiﬁcantly increased in hepatocytes. Distinct gene clusters controlling BA and lipid ho-
meostasis (FGF(R), APO and FABP family members, HMGCS2) and drug metabolism (CYP, UGT and SULT family
members) were signiﬁcantly modulated by CDCA. Importantly, CDCA affected distinct microRNAs, including
miR-34a, -505, -885, -1260 and -552 that systematically correlated in expression with gene clusters responsible
for bile acid, lipid and drug homeostasis incorporating genes, such as e.g. SLCO1B1, SLC22A7, FGF19, CYP2E1,
CYP1A2, APO family members and FOXO3.
Signiﬁcance: Bile acids signiﬁcantlymodulatemetabolic and drug associated gene networks that are connected to
distinct shifts in the microRNAome These ﬁndings give novel insights on how BA enfold metabolic and system
toxic effects.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
Bile acids (BAs) are important endogenous compounds responsible
for the efﬁcient absorption of lipid-soluble compounds in the intestine.
Semiquantitative BA derivatives, such as e.g. obeticholic acid (OCA), are
currently discussed as future treatment option for different metabolic
diseases, such as non-alcoholic fatty liver disease (NAFLD), the most
common liver disease in the western world [1]. There is an urgent
need to better understand how BAs enfold their effects on metabolic
pathways and on their own homeostasis to better estimate safety and
efﬁcacy of these compounds.
The effects of BAs on metabolism are triggered by their interaction
with the nuclear receptor FXR, which leads to improvement of steatosis
and ﬁbrosis in NAFLD [1,2] and a bettering of hepatic insulin sensitivity
[3]. By interactingwith FXR, BAs also regulate their ownhomeostasis via
negative and positive feedback loops [4], thus preventing cells from anthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical characteristics of liver cell donors.
Patient No Gender Age Main diagnosis drugs
1 Female Between 71 and 80 Colon carcinoma and liver metastases None
2 Female Between 70 and 79 GIST tumor None
3 Female Between 51 and 60 Rectosigmoid carcinoma with liver metastases State after 6 cycles of oxaliplatin/folinic acid(FUFOX)
Avastatin
4 Female Between 51 and 60 Liver metastasis after kidney cancer Bisoprolole
L-thyroxine
Zopiclone
Anagrelide
5 Female Between 31 and 40 Hepatocellular carcinoma Metamizole
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lation and homeostasis of BAs are ensured by a coordinated action of BA
uptake and efﬂux transporters. Bile acid transporters include amongst
others the apical sodium-dependent bile acid transporter (ASBT) and
organic solute transporters ɑ/β (OSTα/β) in the intestine, and the
Na+-taurocholate co-transporting polypeptide (NTCP), the organic
anion-transporting polypeptides OATP1B1 and OATP1B3 and the bile
salt export pump (BSEP) in hepatocytes [6].
As ligands for the nuclear receptors FXR, PXR or CAR, BAs regulate
the expression of several genes that are important for both BA homeo-
stasis and drug metabolism, such as e.g. OATP1B1, OATP1B3 and
CYP3A4. This effect may give space for interactions between BAs and
therapeutics and may affect drug exposure margins with consequences
for drug safety and efﬁcacy. By interacting with several other receptor
molecules, besides FXR, such as muscarinic receptors or G protein-
coupled receptors (i.e. TGR5) [7,8], BAs inﬂuence lipid and energy ho-
meostasis. TGR5 triggers weight loss upon activation by BAs [9–11]
and has a positive impact on glucose tolerance by inducing the secretion
of glucagon-like-peptide 1 (GLP-1) from intestinal enteroendocrine
cells [12].
Notwithstanding the role of genetic susceptibility factors in the
pathogenesis of obesity and diabetes [13–16], the complex interplay of
genetically, epigenetically andmicroRNA (miRNA)-driven factors is be-
coming increasingly evident [17–20]. In particular, shifts in the concen-
trations of miRNAs, small noncoding molecules that inhibit mRNAFig. 1. Gene enrichment analysis showing sigtranslation, can lead to rapid changes in protein expression [21].
MiRNAs belong to a relatively small pool of molecules controlling the
expression of major parts of the genome. Thus, expression changes of
only fewmiRNAs can broadly impact the functional integrity of different
metabolic and signaling pathways.
In the current study we investigate the effect of the BA cheno-
deoxycholic acid (CDCA) on the expression of the miRNAome and
mRNAome in primary human hepatocytes (PHHs) and assess to what
extent CDCA induces systematic shifts in gene networks responsible
for BA and lipid homeostasis as well as drug metabolism. BA-induced
shifts in the miRNA proﬁle are set in context to the investigated net-
works to elucidate novel miRNA driven regulatory pathways inﬂuenc-
ing the expression of the mentioned gene networks.
2. Material and methods
2.1. Primary human hepatocytes (PHH)
The study was approved by the Ethics Committee of the Canton of
Zurich, Switzerland (study number EK-680) and the Human Tissue
and Cell Research (HTCR) Foundation. The HTCR-process that included
written informed consent was approved by the Ethics Committee of
the Medical Faculty of the Ludwig Maximilians University (approval
number 025-12) and complied with the Bavarian Data Protection Act.
PHH were obtained from ﬁve patients in Germany who werenaling pathways most affected by CDCA.
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with primary tumors in colon or kidney or because of hepatocellular
carcinoma. The clinical characteristics of the patients are summarized
in Table 1 (supplementary information). PHHs were prepared as earlier
described [22] and kept in six-well plates in hepatocyte maintenance
medium supplemented with UltraGlutamine for approximately 5 h be-
fore further treatment procedures. PHHswere cultured at 37 °C in a hu-
midiﬁed atmosphere containing 5% CO2 at atmospheric pressure.2.2. Cell treatment and whole RNA isolation
PHHs of 5 patients were kept in 6 well plates. 24 h later duplicate
wells of each cell batch were treated with chenodeoxycholic acid
(CDCA) or dimethyl sulfoxide (DMSO) (vehicle control) (both from
Sigma-(both from Sigma-Aldrich, Buchs, Switzerland). One CDCA and
one DMSO treated well of each cell batch were harvested together
24 h or 48 h after cell treatment using TRIzol reagent (Invitrogen, Carls-
bad, CA, USA) for combined DNA and RNA isolation. Subsequently, total
RNA was puriﬁed using the miRNeasy kit from Qiagen (QIAGEN,
Hombrechtikon, Switzerland).Table 2
Effect of CDCA on the expression of genes involved in bile acid homeostasis and drugme-
tabolism in primary human hepatocytes after 48 h.
Gene name⁎ log2 ratio Fold change p-Value FDR
Up-regulated genes
Bile acid homeostasis
FGF19 5.078 33.78 3.541xE-07 9.624xE-05
SLC51B 4.934 30.57 1.091xE-15 2.958xE-12
NR0B2 2.85 7.21 9.207xE-11 8.158xE-08
ABCB11 2.195 4.58 2.194xE-09 1.177xE-06
SLC51A 2.194 4.58 8.15xE-16 2.768xE-12
ABCB4 1.603 3.04 5.099xE-10 3.149xE-07
ABCG5 0.8736 1.83 0.0015 0.065
SLCO1B3⁎⁎ 0.5981 1.51 0.0045 0.124
ABCG8 0.4935 1.41 0.0438 0.434
Drug metabolism
UGT2B10 1.264 2.4 0.0006 0.033
SULT1C2 1.13 2.19 0.0393 0.412
UGT1A8 0.9499 1.93 0.021 0.298
UGT2B4 0.7462 1.68 0.0098 0.196
UGT1A3 0.5976 1.51 0.0269 0.34
UGT1A1 0.5671 1.48 0.0416 0.425
PPARG 0.5001 1.41 0.0431 0.432
Down-regulated genes
Bile acid homeostasis
EPHX1⁎⁎ −0.4618 0.73 0.035 0.389
NR1I3 −0.5675 0.67 0.0106 0.207
SLCO1B1 −0.5869 0.67 0.0046 0.126
BAAT −0.8562 0.55 0.0035 0.107
CYP3A4⁎⁎ −1.734 0.3 2.055xE-13 3.49xE-10
CYP7A1 −6.271 0.01 9.197xE-18 4.686xE-14
Drug metabolism
AHR −0.4569 0.73 0.0413 0.423
UGT1A6 −0.5588 0.68 0.0127 0.229
NR1I3 −0.5675 0.67 0.0106 0.207
SLCO1B1 −0.5869 0.67 0.0046 0.126
UGT2A3 −0.7303 0.6 0.0026 0.09
SULT1B1 −0.7455 0.6 0.0017 0.067
UGT1A7 −0.9585 0.51 0.0423 0.429
SLC22A7 −1.054 0.48 0.0189 0.282
CYP2C8 −1.605 0.33 8.14E-07 b0.001
SULT1E1 −1.679 0.31 0.0014 0.063
SLC22A1 −1.726 0.3 8.55E-12 1.09E-08
CYP1A2 −1.921 0.26 1.05E-07 3.23E-05
CYP1A1 −1.954 0.26 1.96E-05 0.002
UGT1A9 −2.095 0.23 6.84E-05 0.007
CYP2E1 −2.556 0.17 2.03E-21 2.07E-17
⁎ Genes involved in drug metabolism or bile acid homeostasis with a FDR b 0. 46 a
p-value b 0.05.
⁎⁎ Involved in both bile acid homeostasis and drug metabolism or drug transport.2.3. Next generation sequencing
For library preparation the quality of the isolated RNAwas evaluated
using a Qubit® (1.0) Fluorometer (Life Technologies, Carlsbad, CA, USA)
and a Bioanalyzer 2100 (Agilent, Waldbronn, Germany). Only those
samples with a 260 nm/280 nm ratio between 1.8 and 2.1 and a 28S/
18S ratio of 1.5–2 were further processed. 3′ and 5′ RNA adapters
were ligated to total RNA samples (1 μg) using the TruSeq small RNA
Sample Prep Kit v2 (Illumina, Inc., San Diego, CA, USA). Ligated samples
were reverse-transcribed into double-stranded cDNA and fragments
containing TruSeq adapters on both ends were selectively enriched by
polymerase chain reaction (PCR). The small RNA fraction (145–160 bp)
was selected and isolated by polyacrylamide gel electrophoresis. The
quality and quantity of the enriched libraries were validated using a
Qubit® (1.0) Fluorometer and the Caliper GX LabChip® GX (Caliper
Life Sciences, Inc., Hopkinton, MA, USA). The libraries were diluted to
10 nM in Tris-Cl 10 mM, pH 8.5 with 0.1% Tween 20. For cluster genera-
tion and sequencing the TruSeq PE Cluster Kit v3-cBot-HSwas usedwith
10 pMof pooled normalized libraries on the cBOT system (Illumina, Inc.).
Sequencingwas performed on the Illumina HiSeq 2000 using the TruSeq
SBS Kit v3-HS (Illumina, Inc.).Table 3
Effect of CDCA on the expression of genes involved in lipid homeostasis in primary human
hepatocytes after 48 h.
Gene name⁎ log2 ratio Fold change p-Value FDR
Bile acid dependently up-regulated genes
FABP3 2.981 7.9 0.0001 0.009
APOL3 1.464 2.76 1.50E-10 1.09E-07
FGFR2 1.42 2.68 8.02E-06 0.001
LDLR 1.339 2.53 4.20E-13 6.58E-10
PPARD 1.256 2.39 2.18E-06 b0.001
FGF21 1.25 2.38 0.0281 0.347
FASN 1.185 2.27 0.0081 0.174
PCSK9 1.182 2.27 3.95E-06 0.001
S1PR2 1.146 2.21 0.0122 0.224
S1PR1 0.9341 1.91 2.49E-05 0.003
PRKCE 0.8938 1.86 0.0019 0.073
APOA2 0.8007 1.74 0.003 0.098
SCARB1 0.691 1.61 0.0017 0.068
CPT1A 0.6706 1.59 0.0018 0.071
SREBF2 0.6289 1.55 0.0071 0.162
LDLRAP1 0.6005 1.52 0.0061 0.149
NPC1 0.5843 1.5 0.0024 0.085
NPC1L1 0.5734 1.49 0.0014 0.061
SLC27A2 0.5539 1.47 0.0034 0.106
STARD3 0.5293 1.44 0.02643 0.336
FGF2 0.526 1.44 0.02203 0.305
PRKCA 0.5093 1.42 0.0053 0.137
FOXO3 0.5087 1.42 0.0284 0.349
AGPAT2 0.5037 1.42 0.0187 0.281
CREBBP 0.45 1.37 0.0355 0.391
FGFRL1 0.4191 1.34 0.0493 0.459
ATF6B 0.416 1.33 0.0352 0.389
Bile acid dependently down-regulated genes
ACAT1 −0.432 0.74 0.02 0.291
PEX3 −0.4953 0.71 0.0115 0.216
AKR7A3 −0.5941 0.66 0.0041 0.118
APOM −0.6031 0.66 0.0064 0.151
ACADSB −0.6303 0.65 0.0008 0.042
APOC4 −0.7548 0.59 0.0086 0.182
AKR1C1 −0.8871 0.54 0.0161 0.261
APOH −0.9548 0.52 0.0004 0.027
ANGPTL3 −0.9995 0.5 0.0009 0.045
ACAD11 −0.9997 0.5 2.95E-07 8.36E-05
APOA4 −1.059 0.48 0.0135 0.239
AKR1C4 −1.069 0.48 7.84E-08 2.66E-05
FABP7 −1.964 0.26 0.0051 0.134
HMGCS2 −2.128 0.23 0.0001 0.01
⁎ Genes involved in lipid homeostasis (FDR b 0. 46 and p-value b 0.05).
Table 4
Effect of CDCA on the expression of miRNAs in primary human hepatocytes after 48 h.
miRNA⁎ log2 ratio Fold change p-Value FDR
Bile acid dependently up-regulated miRNAs
hsa-mir-552 1.588 3.006 0.0073 0.126
hsa-mir-1260a 1.243 2.367 b0.0001 0.002
hsa-mir-149 1.207 2.309 0.0052 0.115
hsa-mir-1260b 1.186 2.275 b0.0001 0.004
hsa-mir-3651 1.129 2.187 0.0032 0.115
hsa-mir-4485 0.9179 1.889 0.0038 0.115
hsa-mir-3607 0.8542 1.808 0.0043 0.115
hsa-mir-505 0.8398 1.79 0.0035 0.115
hsa-mir-6723 0.7282 1.657 0.0052 0.115
hsa-mir-15b 0.7139 1.64 0.0036 0.115
hsa-mir-328 0.7 1.625 0.0081 0.133
hsa-mir-92a-2 0.6913 1.615 0.0091 0.133
hsa-mir-204 0.5362 1.45 0.0092 0.133
hsa-mir-885 0.4937 1.408 0.0097 0.133
Bile acid dependently down-regulated miRNAs
hsa-mir-34a −0.44 0.737 0.0087 0.133
hsa-mir-30a −0.5096 0.702 0.0055 0.116
hsa-mir-98 −0.6309 0.646 0.0062 0.122
hsa-mir-5590 −0.8854 0.541 0.0036 0.115
hsa-mir-2355 −0.9401 0.521 b0.0001 0.004
hsa-mir-190a −1.1 0.467 0.0022 0.115
hsa-mir-190b −1.266 0.416 0.0096 0.133
hsa-mir-2467 −1.421 0.373 0.0038 0.115
hsa-mir-2114 −1.653 0.318 0.005 0.115
hsa-mir-452 −1.847 0.278 b0.0001 0.002
hsa-mir-486 −2.285 0.205 0.0047 0.115
hsa-mir-486-2 −2.287 0.205 0.0048 0.115
hsa-mir-451b −2.461 0.182 0.0069 0.125
hsa-mir-451a −2.461 0.182 0.0069 0.125
hsa-mir-6503 −2.9 0.134 0.0009 0.073
⁎ Shown are all CDCA dependently modulated microRNAs with a FDR ≤ 0.133 and a
p-value b 0.01.
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RNA sequence reads were quality-checked using the software pack-
age fastqc (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)
which computes various quality metrics for the raw reads.
MessengerRNA sequencing reads were aligned to the genome and
transcriptome using the R statistics package tophat v. 1.3.3 with default
options. Before mapping, the low quality ends of the reads were clipped.
The fragment length parameter was set to 100 bases with a standard de-
viation of 100 bases. Based on these alignments the distribution of the
reads across genomic features was assessed. Isoform expression was
quantiﬁed using the RSEM algorithm (R statistics package rsem) [23].
MicroRNA sequencing reads were aligned to the genome and
quantiﬁed using ncPro-seq (http://www.ncbi.nlm.nih.gov/pubmed/
23044543).
2.5. TaqMan analysis
Messenger RNA quantiﬁcation was performed by transcribing 1.5 μg
mRNA into cDNA using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Rotkreuz, Switzerland) according to the
manufacturer's recommendations. cDNA samples were diluted 1:5
and subsequently used in real-time PCR analyses (RT-PCR) by mixing
2 μl of cDNA and 8 μl of RT-PCR Universal Fast Master Mix speciﬁc to
the respective cDNA target (TaqMan® Gene Expression Assays, Life-
Technologies). β-actin was used to normalize measurements. miRNAs
were quantiﬁed by transcribing 10 ng of extracted RNA into cDNA
(TaqMan® miRNA Reverse Transcription Kit, Applied Biosystems,
Rotkreuz, Switzerland) using stem-loop reverse transcription primers
speciﬁc for the respective miRNA molecule (TaqMan® MicroRNA As-
says, Life Technologies). RT-PCR analyses were performed using
0.67 μl of cDNA and 9.3 μl of the target-speciﬁc RT-PCR Universal Fast
Master Mix (Applied Biosystems). All measurements were performed
in triplicate.
2.6. Statistics
Generalized Linear Models (GLM) were used for statistical analysis
comparing themRNA andmiRNA expression values across the different
treatment conditions after NGS sequencing. One-sample t-tests were
performed to compare the effects of CDCA on the expression of miRNAs
versus DMSO as measured in TaqMan analysis. MiRNAs and mRNAs
were correlated by Pearson's correlation analyses. Correlation diagrams
were obtained using the “corrplot” library of the R-project, ofmRNA and
miRNA expression levels in both CDCA and DMSO treated cell lines, re-
spectively. The statistical packages SPSS 22 and Graphpad Prism version
5 were used for statistical analyses. p-Valuesb 0.05 were considered
signiﬁcant.
3. Results
3.1. Effect of CDCA on genes involved in bile acid synthesis and transport,
lipid, retinol and estradiol metabolism in hepatocytes
PHHs were treated with CDCA or DMSO (empty vehicle) for either
24 or 48 h to study the effect on the mRNA and miRNA expression pro-
ﬁle. Changes in the expression of mRNAs were in general more pro-
nounced after 48 h, and these results are therefore speciﬁcally
discussed in the following section. Expression of 738 genes was signiﬁ-
cantly decreased and expression of 1566 genes was signiﬁcantly in-
creased (False Discovery Rate (FDR) in both cases ≤46%) after 48 h of
CDCA treatment. When considering a FDR up to 30%, expression of
432 genes was signiﬁcantly increased and expression of 1011 genes
was signiﬁcantly decreased in a BA-dependent manner. Gene enrich-
ment analysis using the bioinformatics tool Metacore™ (Thomson
Reuters) revealed that genes with altered expression in response toCDCA belong primarily to gene networks involved in BA and lipid trans-
port and metabolism, as well as estradiol and retinol metabolism (Fig.
1). As expected, CDCA increased expression of FXR-inducible genes
such as ABCB11 (BSEP), FGF19, NR0B2 (SHP) or SLC51A and SLC51B
(OSTα, OSTβ) (Table 2).
Genes involved in the regulation of lipid homeostasis that showed
altered expression in response to CDCA included several members of
the apolipoprotein (APO) and fatty acid- binding protein (FABP) family,
SLC27A2 and STARD3, as well as genes involved in cholesterol, lipid and
fatty acid (FA) synthesis andmetabolism, such as CPT1A,HMGCS2, FASN,
ACAT1 and PCSK9 (Table 3).Within signaling pathways inﬂuencing lipid
homeostasis, LDLR, PRKCA1, PPARδ, AGPAT2 and SREBF2were affected by
CDCA. However, nuclear receptors known to control both BA and lipid
homeostasis, e.g., FXR and LXR, were not signiﬁcantly changed in their
expression.3.2. Effect of CDCA on the expression of drug-metabolizing enzymes
As shown in Table 2, CDCAmodulated the expression of many genes
involved in drug transport and phase I and II drugmetabolism. Amongst
drug-metabolizing cytochrome P450 enzymes, the expression of
CYP2E1, CYP1A1, CYP1A2, CYP2C8, and CYP3A4 was signiﬁcantly de-
creased by CDCA. Amongst phase II enzymes, members of the UDP-
glucuronosyl-transferase (UGT) and sulfotransferase (SULT) families
in particular showed altered expression in response to CDCA. Speciﬁcal-
ly, expression of UGT1A6, 1A7 and 1A9, SULT1E1 and SULT1B1 was
decreased and expression of UGT1A1, 2A8 and 2B10, and SULT1C2 was
increased by CDCA. Transcription factors that regulate drugmetabolism
and excretion, such as the aryl hydrocarbon receptor (AhR), constitutive
androstane receptor (CAR) or peroxisome proliferator-activated recep-
tor γ (PPARγ) also showed altered expression in response to CDCA
(Table 2).
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Whereas only few changes in themiRNA proﬁle were observed after
24 h' treatment of PHHs with CDCA, expression of 52miRNAmolecules
was signiﬁcantly increased and that of 29 miRNAs was signiﬁcantly de-
creased after CDCA treatment for 48 h, as shown in Table 4 (FDR b 0.133,
p b 0.01). Results were conﬁrmed by TaqMan analysis remeasuring and
conﬁrming the CDCA dependent downregulation of 3microRNAs (miR-
6503, miR-486 and miR-223) in three separate hepatocyte batches.
ThesemicroRNAs belong to the group ofmiRNAmoleculesmost strong-
ly affected by CDCA, thus, allowing a conﬁrmatory trend determination
in expression by TaqMan analyses. Other microRNAs affected by CDCA
included miR-552, miR-149, and miR-886 (increased) and miR-34a,
miR-30a, miR-452, miR-486 and miR 190a and 190b (decreased). Figs.
2 and 3 illustrate the CDCA-dependent miRNA proﬁle as a volcano plot
and heatmap, respectively. The heatmap integrated cluster analysis
shows considerable interindividual variability in the miRNA expression
proﬁle following CDCA treatment.
3.4. Correlation of CDCA-induced changes in miRNA levels with mRNA
expression
To evaluate the extent to which miRNAs modulated by CDCA could
inﬂuence the expression of genes involved in BA synthesis, transport
and metabolism, Pearson's correlation analyses were performed. Only
those miRNAs (shown in Table 4) that were predicted to bind to at
least three mRNAs contained in the gene cluster regulating BAFig. 2. Effect of CDCA on the global miRNA proﬁle in ﬁve batches of primary human hepatocyt
corresponding p-values represented as –log10 values (y-axis) when comparing CDCA and emp
p-values b0.05. Green: miRNAs with p-values N0.05. Labeled miRNAs represent molecules thathomeostasis (Table 2), lipidmetabolism (Table 3) and drugmetabolism
(Table 2) were included in the correlation analyses. Binding of miRNAs
was predicted using the bioinformatics tool mirDIP (http://ophid.
utoronto.ca/mirDIP) [24]. As shown in Fig. 4 a distinct cluster of
mRNAs consisting of ABCG5 and ABCG8, SLC22A7, NR0B2, SLC51B,
SLC10A1, CYP3A4 and FGF19 is inversely associated with the expression
of miR-34a upon CDCA treatment. The same gene cluster appears to be
strongly positively correlated with miRNAs −885, −15b and −505,
leading to the hypothesis that miRNA and mRNA clusters may be regu-
lated by common transcriptional pathways. As demonstrated in Fig. 5,
especiallymicroRNA-1260a shows strong inverse correlationswith sev-
eral important genes involved in lipid homeostasis, including AGPAT2,
S1PR2, CPT1A, APOM, AKR1C1 and LDLR upon CDCA treatment pointing
to an inhibitory effect of miR-1260a on the expression of this gene bat-
tery. In contrast to miR-1260a, miRNA-98 that is strongly inversely cor-
related with a gene battery including amongst others NPC1L1, HMGCS2,
AGPAT2, FASN, STARD3 and S1PR2l, loses many of those inverse associa-
tions upon CDCA treatment. This observation points to a less strong reg-
ulatory impact ofmiR-98 on the lipid gene network upon higher hepatic
BA concentrations. Fig. 6 demonstrates the correlation behavior of
mRNAs belonging to the drug metabolism network and distinct
microRNAs. Interestingly miRNA-1260 comes here to the fore again,
now with two family members -1260a and -1260b, showing both
strong positive correlations with the drug metabolizing enzymes
SULT1E1, CYP1A1 and CYP1A2 and CYP2E1. >Less strong but still relevant
positive associations in gene expression are also observed with the UGT
family members UGT2A3, UGT1A7, UGT1A8 and CYP2C8. This observa-
tion suggests a connection between miR-1260 expression and thees. Dots represent the average fold-change of miRNAs shown as log2 values (x-axis) and
ty vehicle (DMSO) treated cells. Red: miRNAs with p-values b0.01. Yellow: miRNAs with
showed a ≥ 2fold increase or decrease.
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ry element of via indirect signaling pathways involving miRNA-1260 as
regulatory compound with impact on e.g. an inhibitory transcription
factor regulating the mentioned gene battery.
4. Discussion
We systematically investigated the effect of CDCA on themRNAome
and miRNAome in human hepatocytes. Using CDCA as a model sub-
stance we demonstrate that BAs have the ability to profoundly change
the transcriptional pattern of gene networks involved in BA and lipid
homeostasis, as well as drug metabolism and disposition. These results
together with our observation that distinct microRNAs appear to be bile
acid dependently changed in expression provide important novel
insights into the regulatory mechanisms behind systematic effects of
BAs that are of both liver therapeutic and toxicological relevance.
CDCA had both enhancing and suppressing effects on the expres-
sion of miRNAs, with the majority of the miRNA molecules having
decreased levels under CDCA treatment. Importantly, we show
that CDCA modulates the expression of distinct miRNAs that appear
to be connected to the expression of gene clusters within the bile
acid, lipid and drug homeostasis associated gene networks.
MicroRNA-34a is CDCA dependently and strongly inversely corre-
lated with key genes involved in BA homeostasis including FGF19,
NR0B2 (SHP), OSTα/β, ABCG5/ABCG8, and SLC22A7. This ﬁndingFig. 3.Heat map showing CDCA-induced changes in miRNA proﬁle clustering in ﬁve batches of
shown. Red: increased miRNAs. Green: decreased miRNAs.suggests a key role of miR-34a in the autoregulation of bile acid ho-
meostasis. We observed a strong downregulation of miR-34a, which
is well in line with results published by Castro et al. (2013), showing
a suppressive effect of ursodeoxycholic acid in patients suffering
from NAFLD [25]. The suppressive effect of CDCA on miR-34a ex-
pression suggests also consequences for NAFLD development, and
the regulation of energy homeostasis and cancer related pathways.
MicroRNA-34a has been shown to SIRT-dependently regulate
brown fat formation. The observed upregulation of serum miR-34a
in NAFLD patients underlines the importance of miR-34a in meta-
bolic diseases [26]. MiRNA-34a has been studied in the context of
cancer development and tumor growth. Associations with disease
development, prognosis and severity have been described for blad-
der, breast, liver and colon cancer as well as lymphoma [27–30]. Be-
sides miR-34a, we detected a distinct microRNA cluster, composed
of miR-885, miR-505 and miR-15b, to be CDCA dependently modu-
lated in expression. These microRNAs were signiﬁcantly upregulat-
ed and showed, in contrast to miR-34a - a positive correlation with
the group of genes inversely associated with the expression of miR-
34a. It is conceivable that these three miRNAs and the associated BA
gene cluster are co-regulated by a common transcriptional pathway
that is activated by CDCA. MiRNA-885 has been shown to play a role
in the pathogenesis of different cancer types [31,32] and has also
been discussed as a potential serum marker for the detection of
ongoing liver pathologies [33]. MiR-15b has been shown to be up-primary human hepatocytes. MiRNAs with changes of at least 50% and p-values b0.05 are
Fig. 4. Pearson's correlation analyses on mRNA and miRNA expression levels taking genes from the BA gene cluster into consideration. DMSO treatment (A), CDCA treatment (B).
MicroRNAs with predicted binding sites in at least three target genes within the bile acid (BA) gene cluster and signiﬁcantly up- analyses on mRNA and miRNA expression levels
taking genes from the BA gene cluster into consideration. DMSO treatment (A), CDCA treatment (B). MicroRNAs with predicted binding sites in at least three target genes within the
bile acid (BA) gene cluster and signiﬁcantly up– or downregulated (FDR ≤ 0.133) were included. Shown are BA mRNA targets that were signiﬁcantly up or downregulated by CDCA
(FDR b 0.46). Blue, positive correlation; red, inverse correlation. A distinct gene cluster composed of important BA homeostasis regulating genes, comprising SLC51A, CYP3A4, SLC22A7,
NR0B2, ABCG5/8, SLC51B, FGF19 and SLC10A1 appears to be strongly inversely correlated with miRNA-34a and positively correlated with the microRNAs miR-885, miR-15b, and miR-
505 upon CDCA treatment (highlighted in green).
53R. Krattinger et al. / Life Sciences 156 (2016) 47–56regulated in NAFLD, and thus, has been suggested to play a role in
the pathogenesis of this disease [34]. MicroRNA-505-3p is discussed
as putative biomarker for primary biliary cirrhosis [35].Fig. 5. Pearson's correlation analyses on mRNA and miRNA expression levels taking genes fr
Analyses included miRNAs signiﬁcantly up- or downregulated and with predicted binding s
mRNA targets signiﬁcantly up- or downregulated. Blue, positive correlation; red, inverse corre
such as S1PR2, CPT1A, APOM, AKR1C1 and LDLR is strongly inversely correlated with the expreCDCA strongly affected genes involved in lipid homeostasis, includ-
ing FGF2, FGFR2, HMGCS2, FABP and APO family members. As potent
ligands for FXR, CDCA and other BAs regulate genes involved inom the lipid gene cluster into consideration. DMSO treatment (A), CDCA treatment (B).
ites in at least three target genes within the lipid gene cluster. Shown are lipid cluster
lation. A distinct gene cluster composed of important lipid homeostasis regulating genes,
ssion of miR-1260a upon CDCA treatment (highlighted in green).
Fig. 6. Pearson's correlation analyses onmRNAandmiRNA expression levels taking genes from theDMgene cluster into consideration.DMSO treatment (A), CDCA treatment (B). Analyses
were performed including thosemiRNAs thatwere signiﬁcantly up- or downregulated and for which binding sites in at least three target genes within the drug transport andmetabolism
(DM) gene cluster were predicted. Shown are DMmRNA targets that were signiﬁcantly up- or downregulated. Blue, positive correlation; red, inverse correlation. A distinct gene battery,
composed of important genes encoding drug metabolizing enzymes, including SULT1E1, CYP1A2, CYP1A1 and CYP2E1 and to a less extent several UGT family members and CYP2C8, is
positively correlated with the expression of miR-1260a and miR-1260b upon CDCA treatment (highlighted in green).
54 R. Krattinger et al. / Life Sciences 156 (2016) 47–56cholesterol, FA, and lipid metabolism, either by direct transcriptional
activation or by FGF-dependent hormonal signaling. In vivo studies
performed in mice have shown that orally administered BAs lead to
a positive effect on body weight [36] and lower the risk for NAFLD
under high-fat diet conditions [2]. Our results support the notion
that BAs modulate the expression pattern of genes involved in lipid
synthesis, transport and metabolism, which could contribute to the
lipid lowering properties repeatedly observed with BAs. In this con-
text we would like to highlight the enhancement of miR-1260 ex-
pression upon CDCA treatment, which was associated with a strong
parallel expression of genes involved in xenobiotica metabolism
(CYP2E1, CYP1A1, CYP1A2) and an inverse expression of important
genes involved in lipid homeostasis (i.e. CPT1A, APOM, LDLR). This
ﬁnding points to a putative coregulatory element regulating the ex-
pression of miR-1260 and the mentioned drug gene group and a
role of this microRNA as regulatory element in lipid metabolism.
MicroRNA-1260 has been recently described as putative biomarker
for paclitaxel-induced apoptosis in HCC cells [37]. Our systematic
analysis of genes involved in drug metabolism and transport show,
that many genes belonging to phase I (CYP1A members, CYP2E1,
CYP2C8), phase II (several genes of the UGT and SULT family) and
phase III (SLC22A1, SLC22A7) are signiﬁcantly modulated by CDCA.
This observation allows the speculation that bile acid derivates may
have the potential to induce drug-drug interactions with other com-
pounds through the modulation of DM gene expression. The impor-
tance of our ﬁndings with regard to a relevant interplay of BAs and
DMEs is further underlined by the fact that distinct and relevant
drug-drug interactions with BAs have been earlier described in
other studies. This comprises amongst others the interaction be-
tween the immunosuppressant Ciclosporine A and bile acids.
Ciclosporine A has been demonstrated to lead to a signiﬁcant accu-
mulation of bile acids and the development of a cholestatic featurein liver derived HepaRG cells [38]. Another important example com-
prises the interaction of the calcium channel blocker nitrendipine
and CDCA. Sasaki and co-workers demonstrated that CDCA and
UDCA are able to inhibit nitrendipine absorption by 50% and thus
to decrease plasma concentrations of nitrendipine to a clinically
relevant extent in healthy individuals [39].
Because the ﬁve batches of PHHs were obtained from patients
resected for liver metastases that were incurred through different ma-
lignant tumors such as colon or kidney cancer, it cannot be excluded
that the underlying pathologies or the existence of genetic polymor-
phisms within the discussed gene clusters or in genes coding for key
transcription factors could induce an additional variance in gene expres-
sion.We speciﬁcally concentrated on the question to what extent CDCA
is able to change the microRNA proﬁle, as also optimally measurable in
the chosen time frame of 48 h. Itwould be interesting to further study in
future studies how and to what extent other epigenetic regulatory
mechanisms, such as e.g. methylation or histone acetylation, are inﬂu-
enced by CDCA. Correlation analyses were done at the miRNA/mRNA
level. Because the regulatory effect of miRNAs is often only observed
at the protein level, we cannot exclude the possibility that the miRNAs
have additional effects on targets that were not detected by assessment
of mRNA levels alone.
We conclude that the expression of the human miRNAome and
mRNAome in PHHs are signiﬁcantly modulated by the bile acid
CDCA, with relevant consequences for the functionality of gene
networks involved in bile acid, lipid and drug metabolism.
CDCA-induced regulation by miRNAs may exert downstream
effects on genes within functionally important networks. Our
ﬁndings give important novel insights into the ability of BA deri-
vates to induce relevant changes in gene networks relevant for
BA compound safety and metabolic disease development such as
obesity and NALFD.
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